Literature DB >> 22841134

Anti-TNFα therapy early improves hemodynamics in local intestinal and extraintestinal circulations in active Crohn's disease.

Philippe Bonnin1, Jessica Coelho, Marc Pocard, Bernard I Levy, Philippe Marteau.   

Abstract

BACKGROUND AND AIMS: Active Crohn's disease affects intestine but may alter other locations as eyes vasculature. Previous studies provide evidence of elevated blood flow velocities (BFv) and volume (BFV) in superior mesenteric artery (SMA). We prospectively studied hemodynamics in feeding arteries of bowel and eyes before and 2 weeks after treatment induction with anti-TNFα.
METHODS: Fifteen patients (5 females, 10 males, 35.4 ± 9.0 years, mean ± SD) with active Crohn's disease for 7.5 ± 7.7 years were enrolled. Ultrasound imaging was performed before and 2 weeks after treatment in SMA and retrobulbar arteries: central retinal (CRA), temporal posterior ciliary (TPCA) and ophthalmic (OA) arteries. Serum markers of inflammation (CRP and fibrinogen), arterial blood pressures (ABP) and skin flow-mediated dilation (sFMD) were measured and patients were compared to 10 control age- and sex-matched subjects.
RESULTS: Before treatment, CRP and fibrinogen plasma concentrations, SMA BFV (339 ± 100 mL/min) were higher in patients than in controls by 8.5-fold (p<0.001), 1.4-fold (p<0.01) and 1.5-fold, respectively (p<0.01). BFv in CRA (3.5 ± 0.7 cm/s) and TPCA (4.4 ± 1.0 cm/s), sFMD (371 ± 469%) were significantly lower than in controls by 83%, 73% and 52% respectively (p<0.05). Two weeks after treatment, CRP and fibrinogen decreased, SMA BFV was normalized (230 ± 39L/min, p<0.01), BFv in CRA, TPCA and OA increased respectively to 4.0 ± 1.1 (p<0.05), 5.2 ± 1.4 (p<0.001), 8.9 ± 3 cm/s (p<0.05). ABP and sFMD remained unchanged.
CONCLUSIONS: In active Crohn's disease, a first anti-TNFα administration rapidly normalized concomitantly plasma inflammatory markers and blood-flows in the mesenteric and retrobulbar arteries without affecting blood pressure and endothelial function.
Copyright © 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22841134     DOI: 10.1016/j.crohns.2012.07.002

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  4 in total

1.  Changes in dynamic contrast-enhanced pharmacokinetic and diffusion-weighted imaging parameters reflect response to anti-TNF therapy in Crohn's disease.

Authors:  Gauraang Bhatnagar; Nikolaos Dikaios; Davide Prezzi; Roser Vega; Steve Halligan; Stuart A Taylor
Journal:  Br J Radiol       Date:  2015-09-24       Impact factor: 3.039

2.  The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile.

Authors:  Lize Bollen; Niels Vande Casteele; Miet Peeters; Gert Van Assche; Marc Ferrante; Wouter Van Moerkercke; Paul Declerck; Séverine Vermeire; Ann Gils
Journal:  Inflamm Bowel Dis       Date:  2015-11       Impact factor: 5.325

3.  Retinal Microcirculation Changes in Crohn's Disease Patients under Biologics, a Potential Biomarker of Severity: A Pilot Study.

Authors:  Eloi Debourdeau; Chloé Charmard; Isabelle Carriere; Julien Plat; Max Villain; Lucile Boivineau; Romain Altwegg; Vincent Daien
Journal:  J Pers Med       Date:  2022-02-07

4.  Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs.

Authors:  Sarah Alrubia; Jialin Mao; Yuan Chen; Jill Barber; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2022-09-03       Impact factor: 5.577

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.